CY1121611T1 - Νανοσωματιδιακο παρασκευασμα που περιλαμβανει εναν αναστολεα της mpges-1 - Google Patents
Νανοσωματιδιακο παρασκευασμα που περιλαμβανει εναν αναστολεα της mpges-1Info
- Publication number
- CY1121611T1 CY1121611T1 CY20191100470T CY191100470T CY1121611T1 CY 1121611 T1 CY1121611 T1 CY 1121611T1 CY 20191100470 T CY20191100470 T CY 20191100470T CY 191100470 T CY191100470 T CY 191100470T CY 1121611 T1 CY1121611 T1 CY 1121611T1
- Authority
- CY
- Cyprus
- Prior art keywords
- mpges
- inhibitor
- nanoparticle preparation
- preparation
- relates
- Prior art date
Links
- 101710096361 Prostaglandin E synthase Proteins 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 102100033076 Prostaglandin E synthase Human genes 0.000 title 1
- 239000002105 nanoparticle Substances 0.000 title 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 102000004226 Prostaglandin-E Synthases Human genes 0.000 abstract 1
- 108090000748 Prostaglandin-E Synthases Proteins 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000003228 microsomal effect Effects 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Η παρούσα εφεύρεση αναφέρεται σε ένα νανοσωματιδιακό παρασκεύασμα που περιλαμβάνει έναν μικροσωματικό αναστολέα συνθάσης-1 προσταγλανδίνης Ε («mPGES-1»). Συγκεκριμένα, η παρούσα εφεύρεση αναφέρεται σε ένα νανοσωματιδιακό παρασκεύασμα που περιλαμβάνει έναν αναστολέα της mPGES-1 και έναν ή περισσότερους επιφανειακούς σταθεροποιητές• μια διαδικασία για την παρασκευή ενός τέτοιου παρασκευάσματος• και τη χρήση του στη θεραπεία του πόνου και της φλεγμονής σε ένα υποκείμενο.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2472MU2014 | 2014-08-01 | ||
PCT/IB2015/055821 WO2016016861A1 (en) | 2014-08-01 | 2015-07-31 | Nanoparticulate formulation comprising a mpges-1 inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1121611T1 true CY1121611T1 (el) | 2020-07-31 |
Family
ID=53969393
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20191100470T CY1121611T1 (el) | 2014-08-01 | 2019-05-03 | Νανοσωματιδιακο παρασκευασμα που περιλαμβανει εναν αναστολεα της mpges-1 |
Country Status (12)
Country | Link |
---|---|
US (2) | US20170135991A1 (el) |
EP (2) | EP3174535B1 (el) |
JP (1) | JP6696082B2 (el) |
CY (1) | CY1121611T1 (el) |
DK (1) | DK3174535T3 (el) |
ES (1) | ES2723429T3 (el) |
HU (1) | HUE044602T2 (el) |
PL (1) | PL3174535T3 (el) |
PT (1) | PT3174535T (el) |
SI (1) | SI3174535T1 (el) |
TR (1) | TR201906040T4 (el) |
WO (1) | WO2016016861A1 (el) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2018338045A1 (en) * | 2017-09-20 | 2020-04-02 | Ichnos Sciences SA | mPGES-1 inhibitor for the treatment of osteoarthritis pain |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5510118A (en) * | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
IT1298575B1 (it) * | 1998-02-06 | 2000-01-12 | Vectorpharma Int | Composizioni farmaceutiche in forma di nanoparticelle comprendenti sostanze lipidiche e sostanze antifiliche e relativo processo di |
US8771740B2 (en) * | 1999-12-20 | 2014-07-08 | Nicholas J. Kerkhof | Process for producing nanoparticles by spray drying |
US7998507B2 (en) | 2000-09-21 | 2011-08-16 | Elan Pharma International Ltd. | Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors |
UA76810C2 (uk) | 2001-12-10 | 2006-09-15 | Мерк Енд Ко., Інк. | Фармацевтична композиція антагоніста рецептора тахікініну у формі наночастинок |
EP1828143B1 (en) | 2004-12-17 | 2013-03-20 | Merck Frosst Canada Ltd. | 2-(phenyl or heterocyclic)-1h-phenantrho[9,10-d]imidazoles as mpges-1 inhibitors |
US7442716B2 (en) | 2004-12-17 | 2008-10-28 | Merck Frosst Canada Ltd. | 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors |
JP2008531721A (ja) * | 2005-03-03 | 2008-08-14 | エラン・ファルマ・インターナショナル・リミテッド | 複素環式アミド誘導体のナノ粒子状組成物 |
UY32138A (es) | 2008-09-25 | 2010-04-30 | Boehringer Ingelheim Int | Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables |
US8778401B2 (en) * | 2008-10-28 | 2014-07-15 | Agency For Science, Technology And Research | Mesoporous material excipients for poorly aqueous soluble ingredients |
US8722093B2 (en) * | 2009-02-23 | 2014-05-13 | NanoRx, Inc. | Policosanol nanoparticles |
UY32470A (es) | 2009-03-05 | 2010-10-29 | Boehringer Ingelheim Int | Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones |
WO2011077313A1 (en) * | 2009-12-22 | 2011-06-30 | Pfizer Inc. | Piperidinecarboxamides as mpges - 1 inhibitors |
TW201305178A (zh) | 2010-10-29 | 2013-02-01 | Glenmark Pharmaceuticals Sa | 作為mPGES-1抑制物的三環化合物 |
WO2012110860A1 (en) | 2011-02-17 | 2012-08-23 | Glenmark Pharmaceuticals S.A. | TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS |
WO2013038308A1 (en) | 2011-09-15 | 2013-03-21 | Glenmark Pharmaceuticals S.A. | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS mPGES-1 INHIBITORS |
TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲mPGES-1抑制劑之三唑酮化合物 |
-
2015
- 2015-07-31 US US15/318,571 patent/US20170135991A1/en not_active Abandoned
- 2015-07-31 PT PT15754023T patent/PT3174535T/pt unknown
- 2015-07-31 WO PCT/IB2015/055821 patent/WO2016016861A1/en active Application Filing
- 2015-07-31 SI SI201530721T patent/SI3174535T1/sl unknown
- 2015-07-31 PL PL15754023T patent/PL3174535T3/pl unknown
- 2015-07-31 HU HUE15754023 patent/HUE044602T2/hu unknown
- 2015-07-31 EP EP15754023.8A patent/EP3174535B1/en active Active
- 2015-07-31 DK DK15754023.8T patent/DK3174535T3/da active
- 2015-07-31 TR TR2019/06040T patent/TR201906040T4/tr unknown
- 2015-07-31 ES ES15754023T patent/ES2723429T3/es active Active
- 2015-07-31 EP EP19159387.0A patent/EP3517104A1/en not_active Withdrawn
- 2015-07-31 JP JP2017504408A patent/JP6696082B2/ja not_active Expired - Fee Related
-
2019
- 2019-05-03 CY CY20191100470T patent/CY1121611T1/el unknown
- 2019-07-31 US US16/527,817 patent/US20200197370A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP3174535B1 (en) | 2019-02-27 |
US20200197370A1 (en) | 2020-06-25 |
US20170135991A1 (en) | 2017-05-18 |
SI3174535T1 (sl) | 2019-06-28 |
EP3517104A1 (en) | 2019-07-31 |
TR201906040T4 (tr) | 2019-05-21 |
WO2016016861A1 (en) | 2016-02-04 |
DK3174535T3 (da) | 2019-05-13 |
JP2017522335A (ja) | 2017-08-10 |
ES2723429T3 (es) | 2019-08-27 |
HUE044602T2 (hu) | 2019-11-28 |
JP6696082B2 (ja) | 2020-05-20 |
PT3174535T (pt) | 2019-05-27 |
PL3174535T3 (pl) | 2019-09-30 |
EP3174535A1 (en) | 2017-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124729T1 (el) | Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου | |
CY1124436T1 (el) | Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια | |
CY1122329T1 (el) | Anti-siglec-8 αντισωματα και μeθοδοι χρhσεως αυτων | |
CY1121826T1 (el) | Προφαρμακα καρβιντοπας και l-ντοπας και η χρηση τους στην αγωγη της νοσου parkinson | |
CY1122510T1 (el) | Μορια αντισωματος σε lag-3 και χρησεις αυτων | |
CY1124407T1 (el) | Ενωσεις αναστολεα αυτοταξινης | |
CY1122730T1 (el) | 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων | |
CY1124131T1 (el) | Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου | |
CY1124926T1 (el) | Νανοσωματιδια που περιλαμβανουν σιρολιμους και μια αλβουμινη για χρηση στη θεραπεια ογκων απο επιθηλιοειδη κυτταρα | |
CY1122803T1 (el) | Διαδικασιες γραμμης παραγωγης σπορων και χρησεις αυτων | |
CY1119199T1 (el) | Αναστολεις cdc7 | |
CY1120729T1 (el) | Πεπτιδια και συνθεσεις για τη θεραπεια τραυματισμου των αρθρωσεων | |
CY1121710T1 (el) | Παρεμβασεις με βαση την αγγειοποιητινη για τη θεραπεια της εγκεφαλικης ελονοσιας | |
EA201791420A1 (ru) | Соединения триазолопиримидина и их применения | |
CY1123033T1 (el) | Σπειροκυκλικοι αναστολεις της καθεψινης c | |
CY1120751T1 (el) | Αναστολεις ετεροδικυκλοαρυλιου του rorc2 και μεθοδοι χρησης αυτων | |
CY1125150T1 (el) | Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου | |
CY1122264T1 (el) | Ppar ενωσεις για χρηση στην αντιμετωπιση των ινωτικων νοσων | |
CO2017005038A2 (es) | Composicones y métodos de tratamiento con profármacos de tizoxanida, un análogo o sal de la misma | |
CY1123216T1 (el) | Αναστολεις της gls1 για την αντιμετωπιση νοσων | |
TR201901348T4 (tr) | Metap-2 inhibitörleri olarak pirolidinon türevleri. | |
CY1123366T1 (el) | Παραγωγα 8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δeκανιου | |
CY1124041T1 (el) | Συνθεσεις που περιλαμβανουν κυκλοσπορινη | |
EA201791174A1 (ru) | Антимикотическое соединение | |
ECSP17029203A (es) | Inhibidor de cinasa aurora a |